Position in GMAB
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$391,172
-$193,641 QoQ
Shares Held
14,240
-34.7% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.39%
of 13F equity value
Holder Rank
#133
of 289 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GMAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gallacher Capital Management LLC holds $2,342,787 across 8 Biotechnology names. GMAB ranks #3 (16.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
10,486 | $570,543 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
5,264 | $412,013 | |
| 3 | GMAB |
Genmab A/S
This page
|
14,240 | $391,172 | |
| 4 | ARGX |
Argenx SE
|
304 | $282,042 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
6,666 | $242,709 | |
| 6 | BNTX |
BioNTech SE
|
2,448 | $227,786 | |
| 7 | INVA |
Innoviva, Inc.
|
9,067 | $205,911 | |
| 8 | ANVS |
Annovis Bio, Inc.
|
5,705 | $10,611 |
All Filings in GMAB
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $391,172 | 14,240 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $584,813 | 21,797 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $664,202 | 21,565 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $664,649 | 21,671 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $358,409 | 17,348 | Shares | Sole | 2025-07-08 | |
| 2025-03-31 | $280,894 | 14,346 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $280,304 | 13,431 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $315,891 | 12,957 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $300,504 | 11,958 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $235,242 | 7,865 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $212,468 | 6,673 | Shares | Sole | 2024-02-06 | |
| No filing history on record for this holder in this stock. | ||||||